QUOTE AND NEWS
Benzinga  Dec 5  Comment 
Gbola Amusa of Chardan Capital said although the AAV-based gene therapy (GT) of Uniqure NV (NASDAQ: QURE has better timing, Spark Therapeutics Inc (NASDAQ: ONCE)has better efficacy in hemophilia B patients. Amusa gave the above comments after...
GenEng News  Dec 5  Comment 
Spark Therapeutics has gained exclusive worldwide rights to Selecta Biosciences’ Synthetic Vaccine Particles (SVP™) platform and exclusive options for up to four additional undisclosed genetic targets, through a deal that could generate up to...
Benzinga  Oct 14  Comment 
Advantage Oil & Gas Ltd (USA) (NYSE: AAV) reported Q3 production and cash flows ahead of expectations. The company achieved impressive cost reductions, Credit Suisse’s David Phung said in a report. He upgraded the rating on Advantage Oil & Gas...
MedPage Today  Jul 25  Comment 
(MedPage Today) -- Infection was the most common cause of death
Benzinga  Jul 7  Comment 
Shares of Regenxbio Inc (NASDAQ: RGNX) could have 320 percent upside, according to Piper Jaffray, which has a price target of $33 on the stock. The $33 target price represents a potential upside of 320 percent from Wednesday's close of...
Benzinga  Jun 1  Comment 
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME)...
GenEng News  Feb 2  Comment 
Researchers from the Perelman School of Medicine at the University of Pennsylvania have reached a milestone in the use of genome editing therapy for treating a rare genetic disorder. The Penn team used the adeno-associated virus (AAV) vector to...
Benzinga  Jan 11  Comment 
Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced the Interministerial Council of...
Benzinga  Jan 6  Comment 
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced positive top-line data from its' Phase II...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki